DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2227162/pacific-biosciences-of-california-pacb-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227162 Feb 15, 2024 - Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227164/dropbox-dbx-tops-q4-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227164 Feb 15, 2024 - Dropbox (DBX) delivered earnings and revenue surprises of 4.17% and 0.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227148/toast-tost-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227148 Feb 15, 2024 - Toast (TOST) delivered earnings and revenue surprises of 36.36% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227151/10x-genomics-txg-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227151 Feb 15, 2024 - 10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227149/roku-roku-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227149 Feb 15, 2024 - Roku (ROKU) delivered earnings and revenue surprises of 15.38% and 2.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227141/doordash-inc-dash-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227141 Feb 15, 2024 - DoorDash, Inc. (DASH) delivered earnings and revenue surprises of -160% and 2.62%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227145/ultragenyx-rare-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227145 Feb 15, 2024 - Ultragenyx (RARE) delivered earnings and revenue surprises of 7.88% and 4.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2227146/atricure-atrc-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227146 Feb 15, 2024 - AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.cnbc.com/2024/02/15/imposter-scams-are-top-fraud-of-2023-ftc-says-how-to-protect-yourself.html Feb 15, 2024 - Imposter scams were the most prevalent consumer fraud last year, the Federal Trade Commission said. Criminals dupe victims by posing as a trustworthy source. 0

https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold. 0